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Background: Sickle cell anaemia (SCA) is a major chronic health problem in Uganda. In patients with SCA, the level
of foetal haemoglobin (HbF) has been found to be important in influencing the clinical course of the disease. Thus
populations with high levels of HbF like those in Saudi Arabia have been described as having a milder clinical
course with fewer complications as compared to populations with lower levels. Disease modifying drugs can
increase the Hb F levels and modify the presentation of SCA.
Methods: This was a cross sectional study in which we determined foetal haemoglobin levels and examined the
relationship between HbF levels and disease severity in SCA patients in Mulago Hospital, Kampala, Uganda. We
consecutively enrolled 216 children aged 1 year to 18 years with SCA attending the Sickle Cell Clinic at Mulago
Hospital whose guardians had given consent. The history included age at onset of initial symptoms and diagnosis,
number of hospitalisations and blood transfusions and other complications of SCA (cardiovascular accidents,
avascular hip necrosis and priapism). A detailed physical examination was performed to assess the current state and
help describe the disease severity for each patient. Blood samples were drawn for HbF levels. HbF levels ≥10% was
defined as high.
Results: Of the 216 children, (80) 37% had HbF levels ≥10%. Significant correlations were observed between HbF
level and several clinical parameters independent of age including age at diagnosis (p value 0.013), number of
hospitalisations (p value 0.024) and transfusions (p value 0.018) since birth.
Conclusion: A third of the children with SCA attending the Sickle cell clinic in Mulago Hospital have high HbF
levels. Higher HbF level is associated with later onset of symptoms and presentation, and less severe disease
characterised by fewer hospitalisations and blood transfusions. We suggest HbF levels should be determined at
initial contact for patients with SCA to guide counselling and identify those who may need closer follow up and
consideration for disease modifying drugs.
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Sickle cell anaemia (SCA), the most common inheritable
disease in Africa, is a leading public health problem in
the region and elsewhere where descendants of Africans
have settled [1]. Worldwide, it is recognized as a major
cause of morbidity and mortality with tremendous social
and economic impact mainly due to the recurrent acute
episodic clinical events called “crises” and hospitaliza-
tions [2]. In Africa, SCA is estimated to contribute to an
equivalent of 5% of under-five deaths, with up to 16% in* Correspondence: lmpalampa@yahoo.com
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distribution, and reproduction in any mediumsome countries such as Nigeria and only half of the
affected children live beyond their fifth birthday [3].
In Uganda, SCA is the most frequent hereditary
haemolytic anaemia. Unlike the situation in developed
countries, where there has been a reduction in morbidity
and mortality mainly because of the availability of spe-
cialised comprehensive care in these countries [4], in
Uganda there is no neonatal screening program and care
is mainly supportive. The disease is therefore associated
with high morbidity and mortality with about 70 – 80%
of children with the disease dying before the age of two
years [5]. Several studies in the 1950s estimated that
20% of the population had the sickle cell trait [6]. Thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tribal groups, being highest among the Bamba (40%),
16-20% among the Baganda, Itesot, Acholi and lowest
among the Karamajong (1-4%) [6,7].
One important factor that has been described as influ-
encing the clinical course and hence disease severity in
SCA is foetal haemoglobin (HbF) level [8]. Populations
with high HbF levels like those in Eastern Saudi Arabia
have been described as having less severe disease with
fewer complications [9] and better survival [10]. Foetal
haemoglobin interferes with the polymerization of HbS
which usually occurs at low oxygen tension in patients
with SCA [11]. In addition, red blood cells with higher
HbF content have prolonged survival hence patients
with high Hb F level also tend to have higher overall Hb
levels [12].
As part of comprehensive care, disease-modifying
drugs (DMDs), most of which act by inducing and rais-
ing HbF levels, are now being used to influence the clin-
ical picture and quality of life in patients with SCA.
These drugs have been shown to be beneficial especially
in those with severe disease [11].
The level of HbF is fairly characteristic of the child’s
level through life after the first year of life and hence this
value has been postulated to be of prognostic import-
ance and predict survival [10,13]. Although the baseline
HbF levels are known in several populations around the
world, hardly any studies have examined HbF levels in
patients in our region or how this may correlate with
clinical disease severity. Such knowledge would be quite
important in assessing the possible impact that introdu-
cing DMDs may have.
In this study, therefore, we aimed to determine the
HbF levels in Ugandan children with SCA and examine
the relationship between HbF level and disease severity.
Methods
Design
This was a cross sectional study that examined the rela-
tionship between HbF level and disease severity.
Study setting
The study was conducted at the Sickle Cell Clinic (SCC)
of Mulago Hospital over a two month period from Janu-
ary to February 2010. Located in the capital, Kampala,
Mulago is the National Referral Hospital for Uganda and
teaching hospital for Makerere University College of
Health Sciences The hospital has a bed capacity of 1,500
and an annual inpatient turnover of 120,000. The SCC is
the only such clinic in Uganda which provides specia-
lized care for both children and adults with SCA. The
clinic runs cost-free daily services and receives about
250–300 patients each week. It has over 6000 registered
patients. Patients are registered after confirmation ofhomozygous SS disease by Hb electrophoresis on cellu-
lose acetate membranes.
The clinic functions as a regular follow up centre and
a day care centre, where non-critically ill patients are ad-
mitted for daytime management. Very ill patients are ad-
mitted to the paediatric emergency ward (Acute Care
Unit) or adult medical casualty unit. The services pro-
vided include counselling, blood transfusions, and
provision of medicines e.g. antimalarial prophylaxis, folic
acid and analgesics. The clinic relies on volunteers for
the delivery of some of the services. Disease modifying
drugs such as hydroxyurea are not routinely provided
for eligible patients.
Study participants
All children aged between 1 and 18 years with confirmed
SCA (Hb SS) attending the clinic during the study
period were eligible. The age of recruitment was from
one year because after the first year, the HbF level is
fairly characteristic for a patient and essentially remains
so throughout life [13]. All children whose parents gave
a written informed consent were included in the study.
We excluded from the study any child who was severely
anaemic (Hb <5 g/dl). Patients who met the study cri-
teria were consecutively enrolled daily. A sample size of
211 was calculated using Kish Leslie formula for cross
sectional surveys using 17% as the expected prevalence
of high HbF level in the cohort [14]. High HbF was
defined as foetal haemoglobin ≥ 10% as used in earlier
studies in Nigeria [14], Senegal [15] and Saudi Arabia
[16].
Study procedure
Identification and screening of eligible patients was car-
ried out by a study nurse at the reception. Parents or
guardians of patients who met the selection criteria were
then approached for consent by the study nurse and, in
addition, assent was sought from children 8 years or
older. Patients whose parents/guardians gave consent
were then recruited and assigned a study number. Data
from clinical history (from both parents/guardians and
available in the clinical notes) and physical exam was
abstracted on to a pre-designed standard case record
form. The descriptions included age at onset of symp-
toms, number of transfusions, hospitalisations, and se-
vere pain episodes in the past year; complications such
as cerebrovascular accidents, priapism, and avascular ne-
crosis; and findings on physical examination.
Four millilitres of peripheral venous blood was drawn
for a complete blood count and foetal haemoglobin
levels. The blood was put in two ethylenediaminetetraa-
cetic acid (EDTA) bottles; one for an automated
complete blood count and the second for determination
of Hb F levels by the alkali denaturation method by
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HbF levels in populations in Nigeria by Fatunde et al
[14], and in Senegal by Diop et al [15]. The basis of this
test is that foetal haemoglobin (HbF) is more resistant to
denaturation in alkaline solution than adult haemoglobin
(HbA). Alkali converts HbA to alkaline hematin. Alka-
line hematin is insoluble and precipitates. HbF is quanti-
tated by measuring the haemoglobin concentration
before and after denaturation. The procedure involves
treating a cyanmethaemoglobin solution with 1.2 N so-
dium hydroxide. Saturated ammonium sulphate is used
to neutralise the alkali after 2 minutes and the mixture
is filtered, read at 420 nm and compared with an ad-
equate dilution of the original cyanmethaemoglobin so-
lution in water. All samples were analysed on the
collection day.
Data analysis
All case record forms were checked for completeness
and accuracy before each participant left the clinic. The
corrected forms were then kept in a study file. The data
recorded on each form was then entered into a database
using EPI-data version 3.1 package using double data
entry to ensure correctness. Data was exported to and
analysed using STATA version 10 software (STATA
Coop, TX). Proportions were compared using Pearson’s
chi square test and reported with the odds ratios with
95% confidence intervals.
Normally distributed continuous variables were sum-
marized as means and compared using the student’s t
test while the median was used for skewed data and
compared using the Mann Whitney U / Rank sum test.
In all cases, p values <0.05 was considered significant.
Ethical considerations
Approval to conduct the study was obtained from
Makerere University School of Medicine Research and
Ethics Committee. Written informed consent was
obtained from legal caretakers of participants and assent
was sought from participants aged 8 years and above be-
fore enrolment into the study. Enrolment was voluntary
and participants could withdraw from the study at any
time without consequences to the patient. Results of the
investigations and any additional important information




Over a two month period, from January to February
2010, five hundred and sixty eight patients attended the
Sickle cell clinic in Mulago Hospital and 216 met our
eligibility criteria and were enrolled. Of the 216 study
subjects, 115 (53.2%) were female and 101 (46.8%) male.The mean (SD) age was 9.3 (4.8) years and the median
age 9 (IQR 5–13) years. The characteristics of the study
participants are summarised in Table 1
Foetal haemoglobin levels
The mean HbF level of the participants was 9.0% (SD
5.58) and the median was 7.9% (IQR 4.7-12.4%). Eighty
patients (37.0%) had high levels of Hb F (≥10%). The
majority of the participants had HbF levels between 2
and 11% with very few having levels greater than 20%.
Patients 5 years and younger on average had higher HbF
levels [mean HbF 11.9% (SD 5.69)] compared to older
patients [mean HbF 7.9% (SD 5.13)] although this differ-
ence was not statistically significant (p value 0.843).
Overall, high HbF level was associated with less severe
disease. In the past year, children with high HbF levels
had significantly fewer hospitalisations (p value 0.036) as
well as fewer transfusions and painful episodes, but this
relationship was not statistically significant (Table 2).
Furthermore, patients with high HbF were less likely to
have had dactylitis or stroke; and of the patients who
developed dactylitis, patients with high HbF levels were
more likely to develop this at an older age, but this rela-
tionship was not statistically significant. There were only
2 patients with avascular necrosis and both had low HbF
levels and 3 with a history of priapism, of which 2 had
low levels HbF levels.
However, when the relationship between HbF level as
a continuous variable and some of the markers of dis-
ease severity was examined, a statistically significant
negative correlation was observed between HbF level
and participant age (r = −0.299, p value = <0.0001), the
total number of transfusions (r = −0.181, p value 0.004),
all cause hospitalisations (r = −0.173, p value 0.006), and
number of severe pain episodes in the past year (r =
−0.104, p value 0.020). The association between HbF
and age at diagnosis (r = 0.151, p value 0.013), all cause
hospitalisations (r = −0.135, p value 0.024) and need for
transfusions (r = − 0.144, p value 0.018) since birth
remained significant even when this was adjusted for age
of the participants Table 3.
Discussion
The influence of foetal haemoglobin levels on disease
manifestation in SCA has hardly been studied in East
Africa. The objective of our study was to examine the
relationship between HbF level and disease severity
among patients with SCA attending the Sickle cell clinic
in Mulago Hospital, Uganda. We found that over one
third of the patients studied had high levels of Hb F and
that higher levels were associated with less severe dis-
ease. In particular, higher levels were associated with
older age at diagnosis, fewer all cause hospitalisations,
transfusions and severe pain episodes.
Table 1 Clinical characteristics of SCA patients by HbF level
Characteristic Patients with High HbF
levels (≥10%) N = 80(%)
Patients with low HbF
levels (<10%) N = 136 (%)
OR (95% CI) p value
Demographic features
Gender
Female 48(60%) 67(49.3%) 1.54 (0.88-2.71) 0.128
Male 32(40%) 69(50.7%)
Age
<5 years 28 (35%) 20 (14.7%) 3.12 (1.58 -6.17) 0.0005
≥ 5 years 52 (65%) 116 (85.3%)
HISTORY
Reason for clinic visit
Sick visit 63(77%) 100 (73.5%) 1.33 (0.69-2.57) 0.390
Routine visit 17 (23%) 36 (26.5%)
Duration of follow up in SCC
< 5 years 54 (67.5%) 52 (38.2%) 3.36 (1.83-6.16) <0.001
≥ 5 year 26 (32.5%) 84 (61.8%)
Transfusions since birth
<3 58 (72.5%) 83 (61%) 1.68 (0.91-3.08) 0.080
≥ 3 22(27.5%) 53 (39%)
Hospitalisations since birth
≤2 48 (60%) 61(55%) 1.82 (1.03- 3.21) 0.036
>2 32 (40%) 75 (45%)
SIGNS
Jaundice
present 53(66.3%) 85 (62.5%) 1.18 (0.66-2.11) 0.580
absent 27 (33.7%) 51 (37.5%)
Palpable spleen
Yes 24 (30%) 28 (20.6%) 1.65 (0.87-3.13) 0.119
No 56 (60%) 108 (79.4%)
Hepatomegaly
Present 40 (50%) 60 (44.1%) 1.27 (0.73-2.21) 0.404
absent 40 (50%) 76 (55.9%)
Haematological parameters
WBC count
<15.0 35 (43.8%) 65 (47.8%) 1.18 (0.67-2.05) 0.566
≥ 15.0 45 (56.2%) 71 (52.2%)
RBC count
<3.0 48 (60%) 80 (58.8%) 1.05 (0.60-1.85) 0.865
≥ 3.0 32 (40%) 56 (41.2%)
Hb level
≥7 g/dl 60 (75%) 98 (72.1%) 1.16 (0.62-2.19) 0.638
<7 g/dl 20 (25%) 38 (27.9%)
PLT level
<400 40 (50%) 66 (48.5% 1.06 (0.61-1.85) 0.835
≥400 40 (50%) 70 (51.5%)
Mpalampa et al. BMC Blood Disorders 2012, 12:11 Page 4 of 7
http://www.biomedcentral.com/1471-2326/12/11
Table 2 Features of disease severity by HbF level
Clinical features Patients with High HbF
levels (≥10%) N = 80(%)
Patients with low HbF
levels (<10%) N = 136 (%)
OR (95% CI) p value
History of dactylitis
Present 53 (66.3%) 106 (77.9%)
Absent 27 (33.7%) 30 (22.1%) 1.80 (0.97-3.53) 0.060
Age at onset of dactylitis
<1 year 37 (69.8%) 78 (73.6%)
≥ 1 year 16 (30.2%) 28 (26.4%) 1.20 (0.57-2.50) 0.617
Age at diagnosis
≤ 1 year 31 (38.8%) 54 (40%)
> 1 year 49 (61.2%) 81 (60%) 1.05 (0.59-1.86) 0.857
Hospitalisations in past year
No 40 (50%) 63 (46.3%) 1.16 (0.67-2.02) 0.602
yes 40 (50%) 73 (53.7%)
Transfusions in past year
No 62 (77.5%) 92 (67.7%) 1.65 (0.87-3.13) 0.123
Yes 18 (22.5%) 44 (32.3%)
Painful episodes in past year
No 27 (33.7%) 41 (30.1%) 1.18 (0.65-2.13) 0.583
Yes 53 (66.3%) 95 (69.9%)
History of stroke
No 76 (95%) 123 (90.4%) 2.00 (0.63-6.43) 0.231
Yes 4 (5%) 13 (9.6%)
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was higher than what was observed in West Africa, par-
ticularly Senegal (25%) [15] and Nigeria (17%) [14]. This
is surprising because patients from Senegal are thought
to have the Senegal haplotype, which is thought to be
associated with a higher HbF level. One difference is that
the Dakar study had adult participants and this may ac-




Age at diagnosis of SCA 0.0
Age at onset of dactylitis −0.0
Number of hospitalisations since diagnosis −0.1
Number of transfusions since diagnosis −0.1
Number of intra-muscular injections received in past year −0.1
Number of hospitalizations in the past year −0.0
Number of blood transfusions in the past year −0.0
WBC Count 0.0
Hb levels −0.0
PLT levels −0.1though Hb F levels are thought to be fairly stable after
the first year of life.
The average HbF level in our population was 9.0%
which is comparable to other studies in Congo [18], Ni-
geria [19], and Saudi Arabia [16] where the mean Hb F
levels were 8.8%, 9.5% and 9.1% respectively.
The relatively higher levels of Hb F in the current
study may be a possible indicator that those with lowcs and HbF levels
ls p-value Adjusted for age
oefficient Pearson Coefficient p-value
99 0.000 - -
47 0.245 0.151 0.013
38 0.291 0.109 0.086
73 0.006 −0.135 0.024
81 0.004 −0.144 0.018
40 0.020 −0.099 0.075
68 0.161 −0.104 0.064
38 0.291 −0.071 0.149
74 0.138 −0.023 0.367
03 0.480 0.024 0.364
05 0.061 −0.105 0.062
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complications of SCA even before the diagnosis is estab-
lished. This way, only the survivors are seen in the clinic
and are now classified as having high Hb F levels and
possibly less severe disease. A prospective study of a
birth cohort and neonatal diagnosis will be able to clarify
this assertion.
The mean age at diagnosis in this study was 2.8 (SD 2.9)
years which is much younger than that in the Dakar [15]
study which was 9.8 years with only 56.7% of their patients
diagnosed by 10 years while 83% of the children in this
study were diagnosed by 5 years. The differences in age at
diagnosis could be because this region in East Africa is a
malaria endemic area and children with sickle cell are
more likely to present with some of the complications of
falciparum malaria such as severe malaria anaemia and
may be tested and diagnosed early. There is also a rela-
tively high prevalence of sickle cell disease and perhaps
the index of suspicion is higher among the clinicians here.
Just about 70% of our study participants had at least
one episode of severe pain requiring a visit to hospital in
the previous year. This is less than the 90% observed in
the Dakar study. One possibility is that the study
included young children who may not be able to articu-
late the severity of their pain clearly, and so the care-
takers may not bring them to hospital for pain. We
found that the number of pain episodes was significantly
related to the HbF levels which is similar to what Platt
found that low HbF levels were significantly associated
with number of pain episodes per year [20].
Complications such as cerebrovascular accidents
(CVA), avascular necrosis and priapism were reported in
only 10% of the study participants which is lower than
what was found in Dakar (25%) [15] possibly because
many of these occur in older patients. The Dakar study
also had a smaller sample size of 60 patients and partici-
pants were prospectively followed up. Of key interest
was that the Dakar study did not report any incident of
CVA and yet this was the main complication in the
present study. However, when our geographic location is
put into consideration, this is where the Bantu haplotype
is mainly found, and this has been associated with more
severe disease.
Only 32% of the patients had never received a blood
transfusion which is less than half of what was described
in Dakar where 68.3% of their patients had never been
transfused. The difference in HbF levels between those
who had never been transfused and those who had
received a transfusion was not statistically significant.
One possibility why so many of the children have
received transfusion may be the high malaria transmis-
sion in the country.
Although the relationship between high HbF as a cat-
egorical value and several markers of disease severitywas not statistically significant, when the correlation
between HbF levels as a continuous variable and the
same markers of disease severity was examined, a sig-
nificant relationship was clearly observed with the age
at diagnosis of SCA, the number of transfusions, hospi-
talisations and the number of severe pain episodes in
the past year. A mathematical modelling of the data
may help in determining the minimum cut-off HbF
level in our setting that may be associated with less se-
vere disease. Knowledge of such a level will be import-
ant for designing trials of treatments that are used to
raise HbF level.
This study had a number of limitations. Many of the
markers of disease severity depended on the participants’
ability to remember events in the past. Thus, the ability
to recall some of these clinical events and the unavail-
ability of some medical records to ascertain the severity
of symptoms may have affected our results. Any docu-
mentation would have been useful in defining the actual
diagnosis for the previous admissions. Secondly, children
who were severely anaemic at enrolment were excluded
because the method of estimation of HbF level would be
inaccurate when the Hb level is below 5 g/dl. This
means some of the patients with severe disease may have
been excluded. We also included all four patients who
had been started on hydroxyurea; however, they had
been on this therapy for a median of two weeks, and so
the effect on HbF level would be minimal. Lastly, we did
not examine for thalassemia and sickle cell haplotypes
which may influence disease severity.
Conclusions
One third of the patients with sickle cell anaemia in
Mulago Hospital have high levels of HbF. High HbF is
associated with less severe disease independent of age;
including age at diagnosis, number of all cause hospitali-
sations and transfusions. We suggest that HbF levels
should form part of the initial investigations in patients
with sickle cell anaemia as this may have value in coun-
selling on patient follow up, prognosis and also consider-
ation for the preferential use of hydroxyurea. A
mathematical modelling of the data from this study may
help in determining the minimum cut-off HbF level in
our setting associated with less severe disease. This level
may be aimed at especially when considering treatments
that are used to raise HbF level.
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